Carisma Therapeutics (CARM) to Release Quarterly Earnings on Monday

Carisma Therapeutics (NASDAQ:CARM) is anticipated to issue its Q4 2025 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($0.1194) per share and revenue of $3.7710 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Carisma Therapeutics Price Performance

NASDAQ:CARM remained flat at $0.00 during midday trading on Monday. 679 shares of the company were exchanged, compared to its average volume of 101,172. Carisma Therapeutics has a 1-year low of $0.00 and a 1-year high of $1.27. The business has a fifty day moving average price of $0.03 and a two-hundred day moving average price of $0.04. The firm has a market capitalization of $20,922.50, a PE ratio of 0.00 and a beta of 1.04.

Institutional Trading of Carisma Therapeutics

An institutional investor recently bought a new position in Carisma Therapeutics stock. Jane Street Group LLC acquired a new position in shares of Carisma Therapeutics Inc. (NASDAQ:CARM) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 150,810 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 0.36% of Carisma Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc is a clinical-stage biotechnology company headquartered in the United States that focuses on harnessing the innate immune system to treat cancer and inflammatory diseases. Through its proprietary CARMA (Chimeric Antigen Receptor Macrophage) platform, Carisma engineers macrophages and other myeloid cells to seek out, engulf and destroy diseased cells while reprogramming the surrounding microenvironment. This approach aims to address key limitations of existing T-cell therapies by leveraging the unique trafficking and immunomodulatory properties of innate immune cells.

The company’s lead oncology candidate, CT-0508, employs a HER2-targeted CAR expressed on macrophages to infiltrate and remodel HER2-positive solid tumors.